Press coverage about Shire (NASDAQ:SHPG) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.923087278091 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- A new Wellbeing Centre for Boulia Shire (northweststar.com.au)
- Shire commended at WA Heritage Awards (colliemail.com.au)
- Shire defends priorities on road funding (thewest.com.au)
- Tourism booms in Dandaragan Shire (thewest.com.au)
- National Heritage Week talk on the history of rugby league in the shire (theleader.com.au)
SHPG stock opened at $157.79 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. The firm has a market cap of $46,571.37, a price-to-earnings ratio of 10.33, a PEG ratio of 1.21 and a beta of 1.31. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15.
The company also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be given a dividend of $0.8937 per share. This is a boost from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. This represents a yield of 1.33%. Shire’s dividend payout ratio (DPR) is presently 6.93%.
A number of brokerages have recently issued reports on SHPG. BidaskClub upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, March 30th. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, March 23rd. Bank of America reiterated a “buy” rating on shares of Shire in a research note on Wednesday, March 28th. ValuEngine cut Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald set a $222.00 price objective on Shire and gave the stock a “buy” rating in a research note on Wednesday, March 28th. Nine equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $204.00.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.